摘要
Whether bleeding should be considered a sufficient sign to justify thorough cancer surveillance in atrial fibrillation (AF) patients receiving nonvitamin K antagonist oral anticoagulants (NOACs) remains unclear. We investigated the relationships between bleeding events and new-onset cancers in AF patients receiving NOACs in a prospective cohort (n = 395, mean follow-up duration of 2.8 years). There were 18 patients who were diagnosed with new-onset cancers 584 ± 372 days after the initiation of NOACs. The patients with new-onset cancers had higher HAS-BLED scores (no, preexisting and new-onset cancer: 1.51 ± 0.81, 1.69 ± 0.87, and 2.11 ± 0.96, respectively; p = 0.006) and a higher incidence of bleeding events (22%, 33%, 67%, respectively; p<0.001) than did patients without new-onset cancers. Bleeding events that preceded the diagnosis of new-onset cancers were independently correlated with new-onset cancers (odds ratio: 7.89, p = 0.001) in the multivariate logistic regression. More than half of the patients (61%) with new-onset cancers had either a significant period of drug interruption for at least 2 months or discontinued NOACs. In conclusions, bleeding in AF patients receiving NOACs could be an alerting sign of new-onset cancers and should prompt the initiation of thorough surveillance to detect early cancers.
| 原文 | English |
|---|---|
| 頁（從 - 到） | 782-786 |
| 頁數 | 5 |
| 期刊 | American Journal of Cardiology |
| 卷 | 123 |
| 發行號 | 5 |
| DOIs | |
| 出版狀態 | Published - 2019 三月 1 |
指紋
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
引用此文
}
Bleeding and New-Onset Cancers in Patients With Atrial Fibrillation Receiving Nonvitamin K Antagonist Oral Anticoagulants. / Hu, Yu Feng; Chang, Shih Lin; Chern, Chang Ming; Wu, Cheng Hsueh; Lin, Yenn Jiang; Lo, Li Wei; Chao, Tze Fan; Chung, Fa Po; Liao, Jo Nan; Chang, Ting Yung; Huang, Ting Chun; Wu, Cheng I.; Liu, Chih Min; Salim, Simon; Vicera, Jennifer Jeanne; Tai, Le Phat; Chen, Shih Ann.
於: American Journal of Cardiology, 卷 123, 編號 5, 01.03.2019, p. 782-786.研究成果: Article
TY - JOUR
T1 - Bleeding and New-Onset Cancers in Patients With Atrial Fibrillation Receiving Nonvitamin K Antagonist Oral Anticoagulants
AU - Hu, Yu Feng
AU - Chang, Shih Lin
AU - Chern, Chang Ming
AU - Wu, Cheng Hsueh
AU - Lin, Yenn Jiang
AU - Lo, Li Wei
AU - Chao, Tze Fan
AU - Chung, Fa Po
AU - Liao, Jo Nan
AU - Chang, Ting Yung
AU - Huang, Ting Chun
AU - Wu, Cheng I.
AU - Liu, Chih Min
AU - Salim, Simon
AU - Vicera, Jennifer Jeanne
AU - Tai, Le Phat
AU - Chen, Shih Ann
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Whether bleeding should be considered a sufficient sign to justify thorough cancer surveillance in atrial fibrillation (AF) patients receiving nonvitamin K antagonist oral anticoagulants (NOACs) remains unclear. We investigated the relationships between bleeding events and new-onset cancers in AF patients receiving NOACs in a prospective cohort (n = 395, mean follow-up duration of 2.8 years). There were 18 patients who were diagnosed with new-onset cancers 584 ± 372 days after the initiation of NOACs. The patients with new-onset cancers had higher HAS-BLED scores (no, preexisting and new-onset cancer: 1.51 ± 0.81, 1.69 ± 0.87, and 2.11 ± 0.96, respectively; p = 0.006) and a higher incidence of bleeding events (22%, 33%, 67%, respectively; p<0.001) than did patients without new-onset cancers. Bleeding events that preceded the diagnosis of new-onset cancers were independently correlated with new-onset cancers (odds ratio: 7.89, p = 0.001) in the multivariate logistic regression. More than half of the patients (61%) with new-onset cancers had either a significant period of drug interruption for at least 2 months or discontinued NOACs. In conclusions, bleeding in AF patients receiving NOACs could be an alerting sign of new-onset cancers and should prompt the initiation of thorough surveillance to detect early cancers.
AB - Whether bleeding should be considered a sufficient sign to justify thorough cancer surveillance in atrial fibrillation (AF) patients receiving nonvitamin K antagonist oral anticoagulants (NOACs) remains unclear. We investigated the relationships between bleeding events and new-onset cancers in AF patients receiving NOACs in a prospective cohort (n = 395, mean follow-up duration of 2.8 years). There were 18 patients who were diagnosed with new-onset cancers 584 ± 372 days after the initiation of NOACs. The patients with new-onset cancers had higher HAS-BLED scores (no, preexisting and new-onset cancer: 1.51 ± 0.81, 1.69 ± 0.87, and 2.11 ± 0.96, respectively; p = 0.006) and a higher incidence of bleeding events (22%, 33%, 67%, respectively; p<0.001) than did patients without new-onset cancers. Bleeding events that preceded the diagnosis of new-onset cancers were independently correlated with new-onset cancers (odds ratio: 7.89, p = 0.001) in the multivariate logistic regression. More than half of the patients (61%) with new-onset cancers had either a significant period of drug interruption for at least 2 months or discontinued NOACs. In conclusions, bleeding in AF patients receiving NOACs could be an alerting sign of new-onset cancers and should prompt the initiation of thorough surveillance to detect early cancers.
UR - http://www.scopus.com/inward/record.url?scp=85058011340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058011340&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2018.11.046
DO - 10.1016/j.amjcard.2018.11.046
M3 - Article
C2 - 30551841
AN - SCOPUS:85058011340
VL - 123
SP - 782
EP - 786
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 5
ER -